A Phase I Gene Therapy Study of FP253/Fludarabine for Prostate Cancer - Related Studies

A Phase I Gene Therapy Study of FP253/Fludarabine for Prostate Cancer (FP253-GDEPT)

This study is currently recruiting participants.

Study NCT00625430. Last updated on May 12, 2008. Information provided by Biotech Equity Partners Pty Ltd

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Prostate Cancer

2	Additional conditions recognized in this trial
		Prostatic Neoplasms

3	More general conditions related to this trial
		Genital Diseases, Male
		Genital Neoplasms, Male
		Neoplasms
		Neoplasms by Site
		Prostatic Diseases
		Urogenital Neoplasms

4	Additional drug interventions recognized in this trial
		Fludarabine
		Fludarabine monophosphate

5	More general drug interventions related to this trial
		Antimetabolites
		Antimetabolites, Antineoplastic
		Antineoplastic Agents
		Immunologic Factors
		Immunosuppressive Agents
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses

6	Sponsors listed in this trial
		Biotech Equity Partners Pty Ltd